| Autor: |
Pim Ittiphakorn, Simon Erridge, Carl Holvey, Ross Coomber, James J. Rucker, Mikael H. Sodergren |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Neuropsychopharmacology Reports, Vol 43, Iss 4, Pp 596-606 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2574-173X |
| DOI: |
10.1002/npr2.12400 |
| Popis: |
Abstract Aim This study aims to analyze the health‐related quality of life (HRQoL) and safety outcomes in attention‐deficit/hyperactivity disorder (ADHD) patients treated with cannabis‐based medicinal products (CBMPs). Methods Patients were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in the following patient‐reported outcome measures (PROMs) at 1, 3, 6, and 12 months from baseline: EQ‐5D‐5L index value, generalized anxiety disorder‐7 (GAD‐7) questionnaire, and the single‐item sleep quality score (SQS). Secondary outcomes assessed the incidence of adverse events. Statistical significance was defined as p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text